Register Before Friday, December 5 & Save Up To $500

FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

A Human Neuronal Based Alpha-Synuclein Assay Useful for Drug Discovery

A Human Neuronal Based Alpha-Synuclein Assay Useful for Drug Discovery

By | 5 December 2025

Human iPSC derived neurons
Imaging and TR-FRET assay
Small molecule and antibody testing